Although serious infusion reactions are a rare event for biological agents used in asthma, in three studies of patients with inadequately controlled asthma and elevated eosinophil levels, IV reslizumab was associated with anaphylactic reactions in three ADA-negative patients, who responded to standard treatment and were withdrawn from the studies [37, 63]. Here, ADA is linked to asthma.